CDR132L
Antisense RNA medical therapy From Wikipedia, the free encyclopedia
CDR132L is an antisense RNA therapy that inhibits MiR-132. It is developed by Cardior Pharmaceuticals to treat heart failure.[1][2][3]
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.